Table 2.

Univariate and multivariate Cox proportional hazards analysis of progression-free survival.

Variable	HR	Univariate	P value	HR	Multivariate	P value
		95% CI			95% CI
Age (years) (≤50 vs. >50)	0.990	0.756–1.298	0.945
FIGO stage (I/II/III/IV)	2.390	1.966–2.907	<0.001	1.478	1.170–1.868	0.001
Histological grade (G1/G2/G3)	1.146	0.973–1.350	0.102
Histological subtype (serous vs. non-serous)	1.075	0.802–1.441	0.629
Residual tumor mass (≤2 cm vs. >2 cm)	3.500	2.582–4.744	<0.001	1.471	1.009–2.144	0.045
Ascites (yes vs. no)	2.127	1.603–2.821	<0.001
CA-125 (U/ml) (<35 vs. ≥35)	2.025	1.267–3.236	0.003
Chemosensitivity (sensitive vs. resistant)	8.390	6.066–11.605	<0.001	7.427	4.891–11.278	<0.001
mGPS (0/1/2)	1.750	1.470–2.083	<0.001	1.327	1.053–1.673	0.017
PNI (<47.2 vs. ≥ 47.2)	2.411	1.807–3.216	<0.001	2.096	1.380–3.185	0.001
CAR (<0.5 vs. ≥ 0.5)	1.751	1.326–2.312	<0.001
LMR (<3.82 vs. ≥ 3.82)	2.271	1.702–3.030	<0.001
BMI (<18.5 vs. ≥ 18.5)	2.615	1.746–3.917	<0.001	1.828	1.155–2.895	0.010

CAR, C-reactive protein/albumin ratio; BMI, body mass index; FIGO, Federation of Gynecologists and Obstetricians; LMR, lymphocyte/monocyte ratio; mGPS, modified Glasgow prognostic score; PNI, prognostic nutritional index.